Virtual increase in the price of the raw medicine, the price of the virtual lifting price!Three pharmaceutical companies under Guangzhou Baiyunshan were notified

[Dahecai Cube News] On August 9th, according to the National Medical Insurance Bureau, recently, the State Medical Insurance Bureau, in accordance with relevant departments, guides relevant provinces to Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd. and Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd. Three companies including Baiyunshan Pharmaceutical General Plant, Guangzhou Baiyunshan Jingxiu Pharmaceutical Co., Ltd., and other three enterprises' drug virtual high prices and set up funds for special investigations.

After investigation, from May 2017 to May 2021, three pharmaceutical manufacturers including Tianxin Pharmaceuticals in order to avoid the "two -vote" policies and supervision, they colluded with more than 50 pharmaceutical agents in the lower reaches, and 87 types of cephalosporidumin and other 87 species of cephalosporidum sulfur were injected. The drugs were cash out by using virtual high -priced prices and transferred funds to downstream drug agents. The amount involves huge amounts, and some of them are used for bribery medical staff or specific relationship persons to carry out drug violations.

The main operation method of cash out is that pharmaceutical manufacturers signed a cooperation agreement with drug agents to increase the designated "dealers" in the procurement of the raw and drug. Double -fold sales to drug manufacturers. Pharmaceutical manufacturers further transmit the virtual high price of raw drugs to the price of factory and bidding network prices in the name of "raising price increases and high production costs". The "dealer" of the raw medicine "dealer" is actually controlled by the drug agent, and the difference in income obtained by the low -selling and high -sale and high -sale raw medicines is cash to the drug agent for medical business bribery. Taking cephalosporin sulfur sulfur as an example, Baiyunshan Pharmaceutical (Preparation Factory) and Baiyunshan Chemical Pharmaceutical Pharmaceutical Pharmaceutical Pharmaceutical Pharmaceutical Pharmaceutical Pharmaceutical Pharmaceutical Pharmaceutical Pharmaceutical Pharmaceutical Pharmaceutical Pharmaceutical Pharmaceutical Pharmacea Instead, the cash -up process is set up, and the "dealer" controlled by the agent controlled by the agent will be transferred to the preparation factory at low buying high. The preparation factory uses the high price of cephalosporin sulfurizer in the cost of the raw medicine drug, which makes the drug production and circulation link on the surface and other policies and regulations to avoid supervision.

At present, three enterprises such as Tianxin Pharmaceuticals have rectified 87 kinds of drugs such as cephalosporin sulfurizes across the country as required and eliminated the virtual heights such as bribery in the current price. The product regulations were stopped purchased. Guangdong Province ordered three companies including Tianxin Pharmaceutical and other related companies to comprehensively rectify marketing models to stop relevant illegal operations. In addition, relevant departments are investigating and punishing in accordance with the law for those suspected of disciplinary, illegal, and crimes.

The State Medical Insurance Bureau will continue to guide the provinces with relevant departments to do a good job of medical prices and recruitment of credit evaluation in accordance with the implementation of corporate rectification and the facts identified by the relevant departments, and cooperate with relevant departments to continue to correct the incompetence in the field of pharmaceutical purchase and sales. The majority of pharmaceutical production and operation companies are requested to take the initiative to regulate their own business behavior, abide by the legal pricing principles of fairness and reasonableness, honesty, and quality and price consistency, and work together to create a righteous market environment and industry ecology.

Intern editor: Xu Xilin | Audit: Li Zhen | Director: Wan Junwei

- END -